AI assistant
Eris Lifesciences Limited — Call Transcript 2019
Jul 24, 2019
61253_rns_2019-07-24_bb356711-35e2-44ee-a361-59e55774c11b.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [562 x 129] intentionally omitted <==
Date: 24[th] July, 2019
| ToThe Department of Corporate ServicesBSE LimitedPhiroze Jeejeebhoy TowersDalal StreetMumbai-400001 | ToNational Stock Exchange of India LimitedExchange PlazaBandra Kurla ComplexBandra (E)Mumbai-400051 |
|---|---|
| Security Code: 540596 | Symbol: ERIS |
SUBJECT: INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)
Dear Sir/Madam,
This is further to our letter dated 20[th] July, 2019 intimating about the date of the Board of Directors Meeting to inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30[th] June, 2019.
We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI LODR, 2015 the Company will hold a conference call for analysts and investors on Monday, 29[th] July, 2019. The detail of the said call is attached herewith and also available on Company’s website.
Thanking you.
For Eris Lifesciences Limited
_________________________ Milind Talegaonkar Company Secretary and Compliance Officer Membership No.: A26493
Encl.:a/a
==> picture [562 x 62] intentionally omitted <==
==> picture [162 x 44] intentionally omitted <==
Axis House, C-2, Wadia International Centre, P.B Marg. Worli, Mumbai 400 025 (India)
==> picture [90 x 54] intentionally omitted <==
Eris Lifesciences Ltd.
Q1FY20 Earnings Call on 29[th] July 2019 hosted by Axis Capital Limited
We are pleased to host, on behalf of Eris Lifesciences Ltd., a conference call for analysts and investors on Monday, 29[th ] July 2019 following the announcement of financial results for the quarter ended June 2019.
The company will be represented by the senior management team, and will initiate the call with a brief discussion on the earnings performance followed by an interactive Question & Answer session.
Details of the conference call are:
| Date | : | Monday, 29th July 2019 |
|---|---|---|
| Time | : | 11:00 AM IST |
| Call Leader | : | Mr. Prakash Agarwal, Axis Capital Limited |
| Country | Dial in numbers | |
|---|---|---|
| Primary number | : | +91 22 6280 1145 |
| +91 22 7115 8046 | ||
| India Local | : | +91 7045671221(Available all over India) |
| International Dial In | ||
| - Hong Kong | : | 800 964 448 |
| - Singapore | : | 800 101 2045 |
| - U K | : | 0 808 101 1573 |
| - USA | : | 1 866 746 2133 |
Copy this URL in your browser: https://services.choruscall.in/ChorusCall/login_en
For further information please contact
Prakash Agarwal Dhagash Vora Dy Head - Research | Executive Director – Pharmaceuticals AVP – Pharmaceuticals Axis Capital Limited Axis Capital Limited Direct: +91 22 4325 1145 Direct: +91 22 4325 1129 Mobile: +91 9820534334 Mobile: +91 9892361383 Email: [email protected] Email: [email protected]